Marable Marcus, Kelly Kaitlin, Cooperrider Jennifer H, Jakubowiak Andrzej, Derman Benjamin A
Department of Medicine University of Chicago Chicago Illinois USA.
EJHaem. 2024 Oct 20;5(6):1260-1264. doi: 10.1002/jha2.1039. eCollection 2024 Dec.
Patients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T-cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits. We evaluated the efficacy and safety of rapid, peripheral, high-dose cyclophosphamide (TurboCy) in 15 patients intending to proceed with CAR T-cell therapy, BsAbs, or long-term regimens. The overall response rate was 80% and the clinical benefit rate was 100% in a heavily pretreated high-risk cohort. Cytopenias were common but no deaths occurred during bridging. All patients proceeded to their next line of intended therapy. TurboCy is an effective and safe bridging strategy.
复发/难治性多发性骨髓瘤患者接受嵌合抗原受体（CAR）T细胞疗法或双特异性抗体（BsAb）治疗时，可能需要桥接治疗以实现获益。我们评估了快速外周高剂量环磷酰胺（TurboCy）在15例打算接受CAR T细胞疗法、BsAb或长期方案治疗的患者中的疗效和安全性。在一个经过大量预处理的高危队列中，总缓解率为80%，临床获益率为100%。血细胞减少很常见，但在桥接治疗期间未发生死亡。所有患者均继续接受下一阶段的预期治疗。TurboCy是一种有效且安全的桥接策略。
